Selective serotonin reuptake inhibitors in pregnancy and infant outcomes

Selective serotonin reuptake inhibitors in pregnancy and infant outcomes.

Adequate treatment of depression during pregnancy is very important for maternal, fetal and neonatal health. Selective serotonin reuptake inhibitors (SSRIs) are commonly used antidepressants. According to one American study, approximately 7% of pregnant women were prescribed an SSRI in 2004-2005. First trimester use of SSRIs, as a group, is unlikely to increase the risk of congenital malformati...

Selective serotonin reuptake inhibitors: depressing perioperative outcomes?

In recent years, prescriptions for antidepressant agents have increased substantially. Selective serotonin reuptake inhibitors (SSRIs) have gradually supervened tricyclic agents as drugs of choice because of their lower toxicity and generally better tolerability. They cause less sedation with fewer anticholinergic effects and are now widely used for the treatment of many conditions including de...

Selective Serotonin Reuptake Inhibitors

It has long been postulated that a deficiency in CNS serotonergic activity is the cause of, or a predisposing factor for, depression. [1] However, the evidence for this association is largely circumstantial and it certainly does not represent an adequate and full model for depression, probably due to there being multiple aetiological factors. [2] Some pharmacological trial data also cast doubt ...

Selective serotonin reuptake inhibitors.

Safety of selective serotonin reuptake inhibitors in pregnancy.

Psychiatric treatment with selective serotonin reuptake inhibitors (SSRIs) may be desirable or necessary during pregnancy; however, the benefit of these treatments must balance the benefits to the mother with any risk to the developing foetus. At the present time, the role of serotonin in normal central nervous system development, as well as the effects of altering serotonin transmission at cri...